Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Haematologica. 2016 Aug;101(8):e339-42. doi: 10.3324/haematol.2015.139667. Epub 2016 May 5.
No abstract available

Keywords: abrogation; bone marrow stromal cell; cell lysis; deratumumab; multiple myeloma; sepantronium bromide.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibody-Dependent Cell Cytotoxicity / drug effects
  • Bone Marrow Cells / physiology
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Synergism
  • Humans
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Immunotherapy / methods
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Naphthoquinones / pharmacology
  • Naphthoquinones / therapeutic use*
  • Stromal Cells
  • T-Lymphocytes, Cytotoxic / drug effects
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • Antibodies, Monoclonal
  • Imidazoles
  • Naphthoquinones
  • daratumumab
  • sepantronium